| KAKEN-PHARMACEUTICAL-CO-LTD |
KAKEN-PHARMACEUTICAL-CO-LTD |
92%
|
Under the terms of the Collaboration Agreement, the Company granted Kaken the exclusive right to develop, manufacture and commercialize tildacerfont for the treatment of congenital adrenal hyperplasi… |
| BMRN |
BioMarin Pharmaceutical Inc. |
72%
|
suance of the Avenue Warrant on March 9, 2026, the shares into which the Avenue Warrant will be issued became fixed and therefore the Company reassessed its accounting treatment under ASC 815-40-15-7… |
| BMRN |
BioMarin Pharmaceutical Inc. |
72%
|
Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: suance of the Avenue Warrant on March 9, 2026, the shares into which the Avenue Warrant will be issued became fixed a… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB graph: . The following table summarizes the … |
| LLY |
Eli Lilly and Company |
72%
|
. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide he… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from SPRB graph: governmental bodies to limit the scope of patent protection both inside and outside the United States for disease tre… |
| NBIX |
Neurocrine Biosciences, Inc. |
72%
|
. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le… |
| NBIX |
Neurocrine Biosciences, Inc. |
72%
|
Reciprocal relationship from NBIX graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from SPRB graph: . The following table summarizes th… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from SNYN… |
| SNYNF |
Sanofi |
72%
|
governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide he… |
| TWST |
Twist Bioscience Corporation |
72%
|
nadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secr… |
| TWST |
Twist Bioscience Corporation |
72%
|
Reciprocal relationship from TWST graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from TWST graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from TWST g… |
| ABC-LLC |
ABC-LLC |
62%
|
suance of the Avenue Warrant on March 9, 2026, the shares into which the Avenue Warrant will be issued became fixed and therefore the Company reassessed its accounting treatment under ASC 815-40-15-7… |
| CELLECT-LLC |
CELLECT-LLC |
62%
|
governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide he… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
edly violating the EU GDPR’s cross-border data transfer limitations. Regulators in the United States and other jurisdictions are also increasingly scrutinizing certain data transfers (including to th… |
| HBM-ALPHA-THERAPEUTICS-INC |
HBM-ALPHA-THERAPEUTICS-INC |
62%
|
. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le… |
| HMNC-HOLDING-GMBH |
HMNC-HOLDING-GMBH |
62%
|
. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le… |
| LICENSE-AGREEMENTS-BIOMARIN-PHARMACEUTICAL-INC |
LICENSE-AGREEMENTS-BIOMARIN-PHARMACEUTICAL-INC |
62%
|
suance of the Avenue Warrant on March 9, 2026, the shares into which the Avenue Warrant will be issued became fixed and therefore the Company reassessed its accounting treatment under ASC 815-40-15-7… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
trial supplies, and other outside services; o other research and development—expenses associated with business operations, quality and regulatory compliance; and ▪ internal expenses, consisting of pe… |
